# US 2021/0171649 A1 · B cell maturation antigen binding proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171649 A1
- Document ID: US20210171649A1
- Status: Published application
- Kind: A1
- Application number: 17/150,272
- Filed: 2021-01-15
- Published: 2021-06-10
- Earliest claimed: 2017-10-13
- Assignees: Harpoon Therapeutics, Inc.
- Applicants: Harpoon Therapeutics, Inc.
- Inventors: Holger WESCHE; Bryan D. LEMON; Richard J. AUSTIN
- Web page: https://patentgrep.com/patent/US20210171649A1

## CPC

- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- C07K 16/18: against material from animals or humans
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are B cell maturation antigen binding proteins with improved binding affinities and improved ability to mediate killing of cancer cells expressing B cell maturation antigen (BCMA). Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of treatment of a cancer or a metastasis thereof using such formulations are further provided.

## Claims

### Claim 1

A method for the treatment or amelioration of a B cell lineage cancer in a subject in need thereof, comprising administering to the subject a single domain B cell maturation agent (BCMA) binding protein comprising complementarity determining regions CDR1, CDR2, and CDR3,
wherein the CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 5, 15, 18, 19, 22, 29, 34, 35, 43, 46, 76, and 95, the CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 118, 121, 122, 125, 126, 129, 133, 137, 147, 156, 164, 173, 174, 190, and 203, and the CDR3 comprises an amino acid sequence set forth as SEQ ID NO: 304, and
wherein the BCMA binding protein is from 80% to 99% identical to the sequence set forth as SEQ ID NO: 472.

### Claim 2 (depends on 1)

The method of claim 1, wherein said single domain BCMA binding protein comprises the following formula:
f1-r1-f2-r2-f3-r3-f4
wherein, r1 is the CDR1; r2 is the CDR2; and r3 is the CDR3; and wherein f1, f2, f3 and f4, are framework residues.

### Claim 3 (depends on 2)

The method of claim 2, wherein f1 comprises SEQ ID NO: 461 or 462.

### Claim 4 (depends on 2)

The method of claim 2, wherein f2 comprises SEQ ID NO: 463.

### Claim 5 (depends on 2)

The method of claim 2, wherein f3 comprises SEQ ID NO: 464 or 465.

### Claim 6 (depends on 2)

The method of claim 2, wherein f4 comprises SEQ ID NO: 466 or 467.

### Claim 7 (depends on 2)

The method of claim 2, wherein r1 comprises SEQ ID NO: 76.

### Claim 8 (depends on 2)

The method of claim 2, wherein r2 comprises SEQ ID NO: 190.

### Claim 9 (depends on 2)

The method of claim 2, wherein r1 comprises SEQ ID NO: 304.

### Claim 10 (depends on 1)

The method of claim 1, wherein said single domain BCMA binding protein has an elimination half-time of at least 12 hours, at least 20 hours, at least 25 hours, at least 30 hours, at least 35 hours, at least 40 hours, at least 45 hours, at least 50 hours, or at least 100 hours, when administered to a subject.

### Claim 11 (depends on 1)

The method of claim 1, wherein said single domain BCMA binding protein is human, humanized, or affinity matured.

### Claim 12 (depends on 1)

The method of claim 1, wherein said single domain BCMA binding protein further comprises an Fc domain.

### Claim 13 (depends on 1)

The method of claim 1, wherein said single domain BCMA binding protein further comprises an anti-cancer agent.

### Claim 14 (depends on 13)

The method of claim 13, wherein the anti-cancer agent is conjugated to the single domain BCMA binding protein.

### Claim 15 (depends on 1)

The method of claim 1, wherein said single domain BCMA binding protein comprises a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOS: 374, 383, 402, 403, 406, 411, 412, and 416.

### Claim 16 (depends on 1)

The method of claim 1, wherein said single domain BCMA binding protein comprises a sequence that is at least 95% identical to a sequence selected from the group consisting of SEQ ID NOS: 374, 383, 402, 403, 406, 411, 412, and 416.

### Claim 17 (depends on 1)

The method of claim 1, wherein said single domain BCMA binding protein comprises an amino sequence set forth as SEQ ID NOS: 374, 383, 402, 403, 406, 411, 412, or 416.

### Claim 18 (depends on 1)

The method of claim 1, wherein said single domain BCMA binding protein recognizes an epitope within the human BCMA protein comprising the sequence set forth as SEQ ID NO: 468.

### Claim 19

A method for the treatment or amelioration of a B cell lineage cancer in a subject in need thereof, comprising administering to the subject a single domain BCMA binding protein comprising complementarity determining regions CDR1, CDR2, and CDR3, wherein the CDR1 comprises the amino acid sequence of SEQ ID NO: 76, the CDR2 comprises the amino acid sequence of SEQ ID NO: 190, and the CDR3 comprises the amino acid sequence of SEQ ID NO: 304, and wherein the BCMA binding protein is from 80% to 99% identical to the amino acid sequence set forth as SEQ ID NO: 472.

### Claim 20

A method for the treatment or amelioration of a B cell lineage cancer in a subject in need thereof, comprising administering to the subject a single domain BCMA binding protein comprising
(i) a CDR1 comprising the sequence of SEQ ID NO: 76, a CDR2 comprising the sequence of SEQ ID NO: 190, and a CDR3 comprising the sequence of SEQ ID NO: 304;
(ii) a CDR1 comprising the sequence of SEQ ID NO: 114, a CDR2 comprising the sequence of SEQ ID NO: 163, and a CDR3 comprising the sequence of SEQ ID NO: 304;
(iii) a CDR1 comprising the sequence of SEQ ID NO: 115, a CDR2 comprising the sequence of SEQ ID NO: 163, and a CDR3 comprising the sequence of SEQ ID NO: 304;
(iv) a CDR1 comprising the sequence of SEQ ID NO: 116, a CDR2 comprising the sequence of SEQ ID NO: 174, and a CDR3 comprising the sequence of SEQ ID NO: 304; or
(v) a CDR1 comprising the sequence of SEQ ID NO: 117, a CDR2 comprising the sequence of SEQ ID NO: 174, and a CDR3 comprising the sequence of SEQ ID NO: 304.
